Mode
Text Size
Log in / Sign up

Review of global assistive product prices across 12 countries shows lower income linked to higher financial burden

Review of global assistive product prices across 12 countries shows lower income linked to higher fi…
Photo by Navy Medicine / Unsplash
Key Takeaway
Note that lower national income is associated with greater financial burden for assistive products.

This publication is a price review that examined a collection of global price data for 120 assistive products selected from an initial list of 300 products prioritized by the WHO Technical Advisory Group on Assistive Technology. The study setting included 12 countries representing a range of income levels and geographic regions. The primary outcome involved the classification of assistive products into five Gross Domestic Product-standardized price ranges. The authors synthesized findings regarding data coverage and affordability across these diverse settings.

The main results demonstrated an inverse relationship between national income level and affordability. Specifically, lower income was associated with greater financial burden for patients requiring these assistive technologies. This finding highlights the economic disparities that exist globally regarding access to essential health products.

Data coverage by country varied substantially. In eight countries, data covered over 75% of products; in the remaining four countries, coverage was below 50%. The authors noted that in four countries, data coverage was below 50% due to challenges such as limited supplier access or time constraints. These limitations affect the completeness of the price data available for analysis.

The review contributed essential evidence to the APL update. While the study provides important insights into global pricing trends, the authors acknowledge that data coverage was incomplete in some regions. The findings suggest that financial burden is a critical barrier in lower-income settings.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
PurposeThe World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) estimate that over 2.5 billion people need assistive technology, yet access remains limited. In response to this pressing need, WHO has maintained, since 2016, a Priority Assistive Products List (APL) with 50 priority assistive products. In 2024, an update was launched to revise and expand the list based on new evidence and stakeholder input. This paper presents the price review component of the update. The review consisted of collecting global price data and classifying assistive products into price ranges to support the decision-making process for the updated APL.Materials and methodsFrom an initial list of 300 products prioritized by the WHO Technical Advisory Group on Assistive Technology, 120 products were selected for the price collection by domain experts. Twelve countries, representing a range of income levels and geographic regions, were chosen for data collection. Focal points in each country gathered the lowest prices for the selected assistive products. The collected price data was then used to classify the products into five Gross Domestic Product-standardized price ranges.ResultsFocal points from all 12 countries submitted price data to varying extents. In eight countries, the data covered over 75% of products, whereas in the remaining four countries, the coverage was below 50%, as focal points faced challenges such as limited supplier access or time constraints. The collected data provided insights into the affordability of assistive products across countries and product categories.ConclusionThe price analysis contributed essential evidence to the APL update and highlighted global disparities in affordability of assistive products. The data showed an inverse relationship between national income level and affordability, where the lower the income, the greater the financial burden assistive products represent.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.